Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.
G protein-coupled receptor
GPR133
adhesion
glioblastoma
glioma
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Glioma is a family of primary brain malignancies with limited treatment options and in need of novel therapies. We previously demonstrated that the adhesion G protein-coupled receptor GPR133 (ADGRD1) is necessary for tumor growth in adult glioblastoma, the most advanced malignancy within the glioma family. However, the expression pattern of GPR133 in other types of adult glioma is unknown. We used immunohistochemistry in tumor specimens and non-neoplastic cadaveric brain tissue to profile GPR133 expression in adult gliomas. We show that GPR133 expression increases as a function of WHO grade and peaks in glioblastoma, where all tumors ubiquitously express it. Importantly, GPR133 is expressed within the tumor bulk, as well as in the brain-infiltrating tumor margin. Furthermore, GPR133 is expressed in both isocitrate dehydrogenase (IDH) wild-type and mutant gliomas, albeit at higher levels in IDH wild-type tumors. The fact that GPR133 is absent from non-neoplastic brain tissue but de novo expressed in glioma suggests that it may be exploited therapeutically.
Sections du résumé
BACKGROUND
BACKGROUND
Glioma is a family of primary brain malignancies with limited treatment options and in need of novel therapies. We previously demonstrated that the adhesion G protein-coupled receptor GPR133 (ADGRD1) is necessary for tumor growth in adult glioblastoma, the most advanced malignancy within the glioma family. However, the expression pattern of GPR133 in other types of adult glioma is unknown.
METHODS
METHODS
We used immunohistochemistry in tumor specimens and non-neoplastic cadaveric brain tissue to profile GPR133 expression in adult gliomas.
RESULTS
RESULTS
We show that GPR133 expression increases as a function of WHO grade and peaks in glioblastoma, where all tumors ubiquitously express it. Importantly, GPR133 is expressed within the tumor bulk, as well as in the brain-infiltrating tumor margin. Furthermore, GPR133 is expressed in both isocitrate dehydrogenase (IDH) wild-type and mutant gliomas, albeit at higher levels in IDH wild-type tumors.
CONCLUSION
CONCLUSIONS
The fact that GPR133 is absent from non-neoplastic brain tissue but de novo expressed in glioma suggests that it may be exploited therapeutically.
Identifiants
pubmed: 32642706
doi: 10.1093/noajnl/vdaa053
pii: vdaa053
pmc: PMC7262742
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa053Subventions
Organisme : NINDS NIH HHS
ID : R01 NS102665
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI130618
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Pharmacol Rev. 2015;67(2):338-67
pubmed: 25713288
Ann N Y Acad Sci. 2019 Nov;1456(1):80-95
pubmed: 31365134
Sci Rep. 2019 Jul 30;9(1):11036
pubmed: 31363148
Ann N Y Acad Sci. 2019 Nov;1456(1):5-25
pubmed: 31168816
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Neoplasia. 2016 Dec;18(12):795-805
pubmed: 27978994
Handb Exp Pharmacol. 2016;234:15-41
pubmed: 27832482
Neurosurgery. 2017 Sep 1;64(CN_suppl_1):177-181
pubmed: 28899043
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Nat Rev Drug Discov. 2019 Nov;18(11):869-884
pubmed: 31462748
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Oncogenesis. 2016 Oct 24;5(10):e263
pubmed: 27775701
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Methods Mol Biol. 2018;1741:31-51
pubmed: 29392688
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Cancer Res. 2005 Jul 15;65(14):6178-88
pubmed: 16024619